77 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Mar 24
Report of Foreign Private Issuer
4:30pm
to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud, and whether effective …
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
1 Sep 23
Condensed Consolidated Financial Statements
4:30pm
an accumulated deficit of approximately $97 million, see “—Liquidity and Capital Resources” below.
Although we provide no assurance, we believe that our
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
16 Jun 23
Condensed Consolidated Financial Statements
4:30pm
no assurance, we believe that our existing funds will be sufficient to continue our business and operations as currently conducted through the fourth
6-K
EX-99.1
nku7tgf
31 Mar 23
Report of Foreign Private Issuer
4:30pm
6-K
EX-10.1
03m1xcll0u449
30 Dec 22
Report of Foreign Private Issuer
4:02pm
424B5
f6v 3gqxwegl5
30 Dec 22
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.2
qi3c4bxy
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
s692eldet xb
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.2
l65ruzye7
27 May 22
Condensed Consolidated Financial Statements
4:39pm
6-K
EX-99.2
tj3oz7 8s
19 Nov 21
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.2
ee7mo
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm
6-K
EX-99.2
5w3vyhfurj1jg8g5
28 May 21
Condensed Consolidated Financial Statements
4:33pm